A hybrid design to optimize preparation of lopinavir loaded solid lipid nanoparticles and comparative pharmacokinetic evaluation with marketed lopinavir/ritonavir coformulation

Journal of Pharmacy and Pharmacology

Volumn 66, Issue 7, 2014, Pages 912-926

  Ravi, Punna Rao ^a   Vats, Rahul ^a   Dalal, Vikas ^a   Murthy, Aditya Narasimha ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

design of experiments; lopinavir; solid lipid nanoparticles; stearic acid; wistar rats

Indexed keywords

LOPINAVIR; LOPINAVIR PLUS RITONAVIR; SOLID LIPID NANOPARTICLE; DELAYED RELEASE FORMULATION; DRUG COMBINATION; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LIPID; NANOPARTICLE; RITONAVIR; STEARIC ACID; STEARIC ACID DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; ENDOCYTOSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NANOEMULSION; NONHUMAN; PARTICLE SIZE; PROCESS OPTIMIZATION; RAT; SCANNING ELECTRON MICROSCOPY; SUSTAINED RELEASE FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION; ZETA POTENTIAL; ANIMAL; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DRUG COMBINATION; DRUG DELIVERY SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INTESTINE ABSORPTION; MALE; WISTAR RAT;

ANIMALS; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; ENDOCYTOSIS; HIV; HIV PROTEASE INHIBITORS; HUMANS; INTESTINAL ABSORPTION; LIPIDS; LOPINAVIR; MALE; NANOPARTICLES; RATS, WISTAR; RITONAVIR; STEARIC ACIDS; TISSUE DISTRIBUTION;

EID: 84902544182     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12217     Document Type: Article

References (31)

1. Freed EO,. HIV-1 Replication. Somat Cell Mol Genet 2001; 26: 13-33.
2. Schrager LK, D'Souza MP,. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 1998; 280: 67-71.
3. Pomerantz RJ,. Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication. Clin Infect Dis 2002; 34: 91-97.
4. Pierson T, et al. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antireteroviral therapy. Annu Rev Immunol 2000; 18: 665-708.
5. Sharma A, et al. Recent Advances in NDDS (Novel drug delivery systems) for delivery of Anti- HIV drugs. Res J Pharm Bio Chem Sci 2010; 1: 78-88.
6. Farmer P, et al. Community-based treatment of advanced HIV disease: introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy). Bull World Health Organ 2001; 79: 1145-1151.
7. Temesgen Z, et al. Current status of antiretroviral therapy. Expert Opin Pharmacother 2006; 7: 1541-1554.
8. du Plooy M, et al. Evidence for time dependent interactions between ritonavir and lopinavir/ritonavir plasma levels following P-glycoprotein inhibition in Sprague-Dawley rats. Biol Pharm Bull 2011; 34: 66-70.
9. Wong HL, et al. Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv Drug Del Rev 2010; 62: 503-515.
10. Kaletra Tablets and Oral Solutions, 2013. Accessed on 22 January 2014. Available from: http://www.medsafe.govt.nz/profs/datasheet/k/Kaletratabsoln.pdf
11. Piacenti FJ,. An update and review of antiretroviral therapy. Pharmacotherapy 2006; 26: 1111-1133.
12. Shafran SD, et al. The effect of low dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med 2005; 6: 421-425.
13. Cai S, et al. Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. Adv Drug Deliv Rev 2011; 63: 901-908.
14. Kingsley JD, et al. Nanotechnology: a focus on nanoparticles as a drug delivery system. J Neuroimmun Pharmacol 2006; 1: 340-350.
15. Aji AMR, et al. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur J Pharm Sci 2011; 42: 11-18.
16. Negi JS, et al. Development of solid lipid nanoparticles (SLNs) of lopinavir using hot self nano-emulsification (SNE) technique. Eur J Pharm Sci 2013; 48: 231-239.
17. Xu X, et al. A quality by design (QbD) case study on liposomes containing hydrophilic API: I. Formulation, processing design and risk assessment. Int J Pharm 2011; 419: 52-59.
18. Zhang Q, et al. Studies on the cyclosporine a loaded stearic acid nanoparticles. Int J Pharm 2000; 200: 153-159.
19. Castelli F, et al. Characterization of indomethacin-loaded lipid nanoparticles by differential scanning calorimetry. Int J Pharm 2005; 304: 231-238.
20. Yue PF, et al. The study on the entrapment efficiency and in vitro release of Puerarin submicron emulsion. AAPS PharmSciTech 2009; 10: 376-383.
21. 3 Full-Factorial Design. AAPS PharmSciTech 2010; 11: 489-496.
22. ICH Topic Q 1 A (R2). Stability Testing of new Drug Substances and Products. (CPMP/ICH/2736/99). 2003 Accessed on 22 January 2014, Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500002651.pdf
23. Vats R, et al. Simple, rapid and validated LC determination of lopinavir in rat plasma and its application in pharmacokinetic studies. Sci Pharm 2011; 79: 849-863.
24. Ravi PR, et al. Effect of ciprofloxacin and grapefruit juice on oral pharmacokinetics of riluzole in Wistar rats. J Pharm Pharmacol 2013; 65: 337-344.
25. Leroux J, et al. New approach for the preparation of nanoparticles by an emulsification-diffusion method. Eur J Pharm Biopharm 1994; 41: 14-18.
26. Hao J, et al. Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design. Int J Nanomedicine 2011; 6: 683-692.
27. Yang Y, et al. Effect of preparation conditions on morphology and release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion method. Chem Eng Sci 2000; 55: 2223-2236.
28. Kadajji VG, et al. Approaches for dissolution testing of novel drug delivery systems. American Pharmaceutical Review. The Review of American Pharmaceutical Business and Technology. 2011 Accessed on 22 January 2014, Available from http://www.americanpharmaceuticalreview.com/Featyred-Articls/ 36880-Approaches-for-Dissolution-Testing-of-Novel-Drug-Delivery-Systems/
29. D'Souza SS, DeLuca PP,. Development of a dialysis in vitro release method for biodegradable microspheres. AAPS PharmSciTech 2005; 6: E323-E328.
30. Roger E, et al. Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis. J Cont Rel 2009; 140: 174-181.
31. Porter C, et al. Lipids and lipid based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 2007; 6: 231-248.